NOTA AIFA 100 – Prescrizione degli inibitori del SGLT2, degli agonisti recettoriali del GLP1, degli inibitori del DPP4 e loro associazioni nel trattamento del diabete mellito tipo 2
25 gennaio 2022
Leggi
Sodium-glucose cotransporter 2 inhibitors, glucagon-like peptide-1 receptor agonists, and dipeptidyl peptidase-4 inhibitors, and risk of hospitalization
Lyu B, Grams ME, Chang A, et al.
Am J Cardiol. 2022;165:124-130.
Leggi
Glycemic outcomes in baseline hemoglobin a1c subgroups in the International Diabetes Closed-Loop (iDCL) Trial
Ekhlaspour L, Town MA, Raghinaru D, et al.
Diabetes Technol Ther. Pub. online 12 January 2022
Leggi
Risk factor analysis for type 2 diabetic patients about hypoglycemia using continuous glucose monitoring: Results from a prospective observational study
Uemura F, Okada Y, Mita T, et al.
Diabetes Technol Ther. Pub. online 20 January 2022.
Leggi
Outcomes of patients with diabetes versus patients without diabetes hospitalized with acute heart failure
Wan SH, Slusser JP, Hodge DO, Chen HH
Am J Cardiol. 2022;165:65-71
Leggi
Predictors of cardio-kidney complications and treatment failure in patients with chronic kidney disease and type 2 diabetes treated with SGLT2 inhibitors
Kovesdy C , Schmedt N, Folkerts K, et al.
BMC Med. 2022;20(1):2
Leggi
Comprehensive management of cardiovascular risk factors for adults with type 2 diabetes: a scientific statement from the American Heart Association
Joseph JJ, Deedwania P, Acharya T, et al.
Circulation. 2022;CIR0000000000001040
Leggi
Genetic risk score enhances coronary artery disease risk prediction in individuals with type 1
Lithovius R, Antikainen AA, Mutter S, et al.
Diabetes Care. 2022;dc210974
Leggi
Trends in all-cause mortality among people with diagnosed diabetes in high-income settings: a multicountry analysis of aggregate data
Magliano DJ, Chen L, Carstensen B, et al.
Lancet Diabetes Endocrinol. 2022;S2213-8587(21):00327-2
Leggi
Effect of dapagliflozin on hematocrit in patients with type 2 diabetes at high cardiovascular risk: observations from DECLARE-TIMI 58
Kolkailah AA, Wiviott SD, Raz I, et al.
Diabetes Care. 2022;dc211668
Leggi